Cargando…

A US Retrospective Claims Analysis Comparing Healthcare Costs of Patients Transitioning from Immediate-Release Oxycodone to Two Different Formulations of Extended-Release Oxycodone: Xtampza ER or OxyContin

PURPOSE: Opioid therapy for managing chronic pain remains a challenge, as providers must weigh the medical benefit to the patient with the risk of adverse events. Manipulation of many extended-release (ER) opioid formulations may lead to increased serious medical outcomes or death. The economic burd...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olatoke, Oluwadara, Zah, Vladimir, Stanicic, Filip, Vukicevic, Djurdja, Yfantopoulos, Platonas, Thompson, Christy, DeGeorge, Michael K, Passik, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901186/ https://www.ncbi.nlm.nih.gov/pubmed/35264862 http://dx.doi.org/10.2147/CEOR.S340290

Ejemplares similares

Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation†
por: Sessler, Nelson E, et al.
Publicado: (2014)

Healthcare Costs And Resource Utilization In Chronic Pain Patients Treated With Extended-Release Formulations Of Tapentadol, Oxycodone, Or Morphine Stratified By Type Of Pain: A Retrospective Claims Analysis, 2012–2016
por: Zah, Vladimir, et al.
Publicado: (2019)

Oral Human Abuse Potential of Oxycodone DETERx(®) (Xtampza(®) ER)
por: Kopecky, Ernest A., et al.
Publicado: (2016)

Pharmacokinetics, Tolerability, and Safety of Intranasal Administration of Reformulated OxyContin(®) Tablets Compared with Original OxyContin(®) Tablets in Healthy Adults
por: Perrino, Peter J., et al.
Publicado: (2013)

The controversy surrounding OxyContin abuse: issues and solutions
por: Jayawant, Sujata S, et al.
Publicado: (2005)

OxyContin and the McDonaldization of chronic pain therapy in the USA
por: Hughes, Jordan, et al.
Publicado: (2019)

Analgesic efficacy, safety, and tolerability of a long-acting abuse-deterrent formulation of oxycodone for moderate-to-severe chronic low back pain in subjects successfully switched from immediate-release oxycodone
por: Markman, John, et al.
Publicado: (2018)

Oxycodone Controlled Release in Cancer Pain Management
por: Biancofiore, Giuseppe
Publicado: (2006)

An Evaluation of the Effect of the OxyContin Reformulation on Unintentional Fatal and Nonfatal Overdose
por: Beachler, Daniel C., et al.
Publicado: (2022)

Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350
por: Poulsen, Jakob L, et al.
Publicado: (2018)

Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
por: Webster, Lynn R., et al.
Publicado: (2019)

Profile of extended-release oxycodone/acetaminophen for acute pain
por: Bekhit, Mary Hanna
Publicado: (2015)

Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone
por: Nataatmadja, Melissa, et al.
Publicado: (2016)

Real-world Medicare Healthcare Costs of Patients with Dupuytren’s Contracture Treated with Collagenase or Fasciectomy
por: Zah, Vladimir, et al.
Publicado: (2022)

Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial
por: Lee, Kyung-Hee, et al.
Publicado: (2017)

Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients
por: Lauretti, G R, et al.
Publicado: (2003)

Trends and uptake of new formulations of controlled‐release oxycodone in Canada
por: Gomes, Tara, et al.
Publicado: (2018)

Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics
por: Coplan, Paul M, et al.
Publicado: (2013)

Monitoring of Internet Forums to Evaluate Reactions to the Introduction of Reformulated OxyContin to Deter Abuse
por: McNaughton, Emily C, et al.
Publicado: (2014)

OxyContin was submitted and justifiably approved by the agency as a 12-hour dosage form
por: Fudin, Jeffrey, et al.
Publicado: (2016)

Effects of an Oxycodone Conjugate Vaccine on Oxycodone Self-Administration and Oxycodone-Induced Brain Gene Expression in Rats
por: Pravetoni, Marco, et al.
Publicado: (2014)

Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets
por: Franke, Ryan M, et al.
Publicado: (2015)

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
por: Setnik, Beatrice, et al.
Publicado: (2017)

Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective
por: Ferrarese, Fabio, et al.
Publicado: (2008)

Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients
por: Fujiwara, Yutaka, et al.
Publicado: (2014)

Pain therapy with oxycodone/naloxone prolonged-release combination: case report
por: Błaszczyk, Feliks, et al.
Publicado: (2013)

Intractable restless legs syndrome: role of prolonged-release oxycodone–naloxone
por: de Biase, Stefano, et al.
Publicado: (2016)

Perceptions of Community-Dwelling Patients and Their Physicians on OxyContin® Discontinuation and the Impact on Chronic Pain Management
por: Chang, Feng, et al.
Publicado: (2017)

ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer
por: Wong, Aaron K., et al.
Publicado: (2022)

Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets
por: Kim, Ju-Young, et al.
Publicado: (2015)

Developments in managing severe chronic pain: role of oxycodone–naloxone extended release
por: Fanelli, Guido, et al.
Publicado: (2015)

The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting
por: Coplan, PM, et al.
Publicado: (2016)

Methodological Issues on a Clinical Trial to Test Tapentadol Prolonged release vs. Oxycodone/Naloxone Prolonged release
por: Bacallao, Jorge, et al.
Publicado: (2016)

Reformulation of controlled-release oxycodone and pharmacy dispensing patterns near the US–Canada border
por: Gomes, Tara, et al.
Publicado: (2012)

Oxycodone hydrochloride immediate-release analgesic for managing severe pain: abuse-deterrent formulations
por: Kibbe, AH, et al.
Publicado: (2018)

Controlled Release of Oxycodone as an Opioid Titration for Cancer Pain Relief: A Retrospective Study
por: Zhao, Shen, et al.
Publicado: (2020)

On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data
por: Pappin, Jessie, et al.
Publicado: (2022)

Use of Oxycodone in Pain Management
por: Moradi, Mohammad, et al.
Publicado: (2012)

Epidural Oxycodone for Acute Pain
por: Piirainen, Panu, et al.
Publicado: (2022)

Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain
por: Pergolizzi, Joseph, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u26klcfo68oc68qhsgvue9ncqt